COALITION study: Glofitamab with R-CHOP or Pola-R-CHOP in high-risk LBCL

Results from the phase II COALITION trial (NCT04914741) evaluating the safety and efficacy of glofitamab in combination with rituximab + cyclophosphamide + doxorubicin + vincristine + prednisone (R-CHOP) [Arm A] or polatuzumab vedotin + R-CHOP (Pola-R-CHOP) [Arm B] in 80 patients aged ≤65 years with high-risk (HR) large B-cell lymphoma (LBCL) were published by Minson et al. in the Journal of Clinical Oncology. The primary objective was safety and treatment deliverability. 

Key data: Each treatment arm achieved a median relative dose intensity (RDI) of >94%. Cytokine release syndrome (CRS) occurred in 21% of patients (all Grade ≤2 and manageable). At a median follow-up of 20.7 months, the overall response rate (ORR) was 100%, with a complete metabolic response (CMR) rate of 98%. The estimated 2-year progression-free survival (PFS) and overall survival (OS) were 86% and 92%, respectively. 

Key learning: The findings demonstrate that glofitamab combined with R-CHOP or Pola-R-CHOP is a feasible and effective treatment, with high rates of durable responses in younger patients with HR LBCL, showing promise as a potential first-line therapy in this population.